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Abstract
Background: Although information about the incidence of viral respiratory illnesses and their associated cost can
help health officials explore the value of interventions, data are limited from middle-income countries.
Methods: During 2008–2010, we conducted a prospective cohort study and followed ~1,800 Argentinian children aged
≤5 years to identify those children who were hospitalized or who sought care at an emergency room with any acute
respiratory infection sign or symptom (e.g., rhinorrhea, cough, wheezing, tachypnea, retractions, or cyanosis). Respiratory
samples were obtained for respiratory syncytial virus, influenza, parainfluenza, adenovirus, and metapneumovirus testing
by immunofluorescence and for rhinovirus by real-time reverse transcription polymerase chain reaction.
Results: The incidence of respiratory syncytial virus (24/1000 children-years), human metapneumovirus (8/1000
children-years), and influenza (8/1000 children-years) illnesses was highest among hospitalized children aged
<6 months and decreased among older children. In contrast, the incidence of rhinovirus was highest (12/1000
children-years) among those aged 6–23 months. In the emergency room, the incidence of rhinovirus was 459;
respiratory syncytial virus 352; influenza 185; parainfluenza 177; metapneumovirus 130; and adenovirus 73/1,000
children-years. The total cost of hospitalization was a median of US$529 (Interquartile range, US$362–789).
Conclusions: Our findings indicate that respiratory viruses, in particular rhinovirus, respiratory syncytial virus,
metapneumovirus, and influenza may be associated with severe illness causing substantial economic burden.
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Background
Respiratory viruses are the major cause of acute respira-
tory infections (ARI) which can range from mild and
self-limited to severe and even fatal disease. The most
frequent viruses related to these infections are respira-
tory syncytial virus (RSV), influenza, adenovirus,
parainfluenza, and metapneumovirus (HMPV) [1–4]. In
addition, human rhinoviruses, which have been trad-
itionally described as the cause of the common cold, are
also associated with respiratory infections of the lower
tract [5].
Prevalence of these viruses is well known in different
populations while data on virus incidence are scarce
from countries like Argentina. Only 13 % of studies on
influenza-associated hospitalizations, for example, have
been published from low- and middle-income countries
[2]. Disease burden is part of the information necessary
to help ministries of health and the World Health
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Organization explore the potential value of ARI preven-
tion and control [6]. Furthermore, baseline disease bur-
den data are relevant when evaluating the introduction
or expansion of vaccines, infection control measures,
and hand washing and respiratory hygiene campaigns
which aim to prevent and control respiratory virus
transmission [7]. In addition, virus specific incidence can
be useful when exploring the potential utility of new vac-
cines under development that aim to protect children
against RSV and other viruses.
Currently, the only respiratory viral vaccines licensed
for use among children are influenza vaccines. Safe and
effective influenza vaccines are available for preventing
influenza illness among children aged >6 months [8]. Al-
though children aged <6 months are ineligible for influ-
enza vaccination, they might be protected if their
mothers are vaccinated during pregnancy [9]. The ma-
jority of countries in the Americas vaccinate children to
prevent influenza illness and its associated economic
burden [10, 11]. Historically, countries in the Americas
could obtain influenza vaccines through the Pan
American Health Organization Revolving Fund for ap-
proximately US$4/dose. This has to be administered an-
nually and in 2 doses among children who have not
previously been vaccinated. Therefore, although each in-
fluenza vaccine dose can be administered for a modest
cost, influenza vaccination programs can represent an
important annual expenditure for middle-income coun-
tries in the Americas.
Argentina, a middle-income country in South
America, invests in annual respiratory hygiene cam-
paigns and vaccinates children aged 6 months–2 years
to protect them against influenza virus illness [10]. How-
ever, information is limited about the value of these in-
vestments. Indeed, data regarding the age-stratified rates
of respiratory virus illnesses among very young children
or their associated costs are unavailable. In this paper,
we report on the etiology-specific acute respiratory ill-
ness incidence, among a cohort of children aged ≤5 years
and costs incurred during their hospitalizations.
Methods
Design and study objectives
From June 2008 to December 2010, we conducted a pro-
spective cohort study of acute respiratory infections
among children aged ≤5 years living in Buenos Aires,
Argentina. A primary objective was to quantify the inci-
dence of laboratory-confirmed influenza among hospi-
talized children in order to explore the potential value of
expanding influenza vaccine use among children in
middle-income countries like Argentina. To provide fur-
ther context to our reader, we also aimed to estimate the
incidence of other respiratory viruses among hospital-
ized children, the cost of hospitalization for acute
respiratory illness, the incidence of respiratory viruses
among children seeking care in emergency rooms, the
prevalence of respiratory virus detections among asymp-
tomatic children, and the impact of applying different
commonly used case-definitions to the incidence of
respiratory viruses.
Study population
We followed persons affiliated to Centro de Educación
Médica e Investigaciones Clínicas (CEMIC), a non-profit
health insurance plan with approximately 1,800 members
who are children aged ≤5 years. These children were from
primarily middle-income families that paid a monthly fee
to CEMIC for preventive health care and for access to its
two hospitals and emergency room clinics.
Enrolment of study children
Medical staff enrolled all CEMIC children who were
hospitalized at CEMIC for the management of an acute
respiratory infection. Specifically they sought to enroll
hospitalized children with any acute respiratory infection
sign or symptom (e.g. rhinorrhea, otodynia, cough,
wheezing, tachypnea, retractions, or cyanosis). For this
study, children with immunosuppression, cardiopathy,
and chronic pulmonary, metabolic, and genetic diseases
were excluded. The primary goal was to quantify the
burden of respiratory viruses among previously healthy
community children who did not have severe pre-
existing conditions.
Medical staff also enrolled a convenience sample (i.e.,
an easily accessible, non-random sample) of children
presenting to the Saavedra emergency department in
Ave. Galván 4102 with any acute respiratory sign or
symptom because there were insufficient resources for a
random selection. Similarly, medical staff enrolled a con-
venience sample of asymptomatic children who visited
CEMIC for preventive care and denied any respiratory
symptom within two weeks prior to their visit. These
asymptomatic children could belong to CEMIC or any
other health care plan. We did not follow up with the
asymptomatic controls after we sampled to determine if
they subsequently developed symptoms.
Demographic and clinical data collection
Parents or guardians were asked by the pediatrician
about their children’s demographic and clinical charac-
teristics. Data were recorded in a standardized question-
naire. Data included children’s age, gender, preexisting
medical conditions (i.e., prematurity, low birth weight
[<2,500 g] [12], reactive airway disease, or atopy), history
of breastfeeding, and second-hand exposure to tobacco
smoke. In addition, children’s vaccination cards were
used to record the status of influenza vaccination and
other mandatory vaccines recommended by Argentina
Marcone et al. BMC Infectious Diseases  (2015) 15:447 Page 2 of 9
Ministry of Health (e.g. haemophilus influenza type B,
hepatitis B and oral polio vaccine) [13]. Medical staff re-
corded children’s respiratory signs and symptoms at the
time of presentation. For hospitalized patients, data
about clinical course of hospitalization, including length
of stay and oxygen therapy, admission to an intensive
care unit, and mechanical ventilation were recorded.
Sample collection and respiratory virus detection
Respiratory samples (i.e., nasopharyngeal aspirates from
hospitalized children and nasopharyngeal swabs from
outpatients) were obtained from children who presented
within 5 days of symptom onset. Samples were placed in
viral transport media at ~4 °C and were immediately
sent to CEMIC Virology Laboratory to be processed for
rapid antigen detection by immunofluorescence (IF) [1].
RSV, adenovirus (AdV), influenza A (FluA), influenza B
(FluB), and parainfluenza (PIV) 1, 2, or 3 were detected
by indirect IF with monoclonal antibodies (Millipore
Corporation, Massachusetts USA); human metapneumo-
virus was detected by direct IF (bioMérieux, France). An
immunofluorescence assay was unavailable for rhino-
virus. Therefore, an aliquot of the original sample was
stored at −70 °C for rhinovirus detection by real-time
RT-PCR. Viral RNA/DNA extraction was manually per-
formed by using the QIAamp®MinElute® Virus Spin
(Qiagen GmbH, Germany), according to the manufac-
turer’s recommendations. Real-time RT-PCR was per-
formed by amplifying a segment of the 5’ non-coding
region of the genome, in a LightCycler® 2.0 (Roche Diag-
nostics, France) [14].
Incidence calculations
To estimate the annual incidence of acute respiratory in-
fections, we divided the number of CEMIC children ad-
mitted at CEMIC hospital with an acute respiratory
infection by the number of children who were members
of the CEMIC plan in 2008, 2009, and 2010 [15]. We as-
sumed each child enrolled in the CEMIC plan was at
risk of developing an acute respiratory infection and
subsequent complications requiring hospitalization.
CEMIC children would predominantly seek care at the
CEMIC hospital because their families prepaid for such
care through the plan. We assumed each child who was
a member of the CEMIC plan during 2008 contributed
½ year of person-time to the analysis because the study
started in June-December of 2008. Each child who was a
member of the CEMIC plan during 2009 and 2010 con-
tributed two years of person-time to the analyses be-
cause medical staff searched for these admissions year-
round. Finally, we determined the proportion of children
admitted to the hospital with any acute respiratory sign
or symptom that met commonly used respiratory case-
definitions (Table 1) to determine their impact on inci-
dence calculations.
We also used a multiplier to estimate the incidence of
emergency room visits for acute respiratory infections
model [6] because we did not have the resources to en-
roll all children seeking care at the emergency room.
First we reviewed emergency room records to determine
the number of CEMIC children who sought care for
acute respiratory illnesses each month during 2008–2010.
We assumed that CEMIC children seeking care for acute
respiratory signs and symptoms had approximately the
same probability of testing positive for a specific respira-
tory virus than all children sampled by convenience dur-
ing the same month and year [16]. We estimated the
number of CEMIC children that would have tested posi-
tive for respiratory viruses if all had enrolled in the study
by multiplying the monthly number of CEMIC children
seeking care at emergency room by the proportion that
provided respiratory samples and subsequently tested
positive for viruses from CEMIC and other health plans.
We divided this numerator by the person-time CEMIC
children were enrolled during the June 2008-December
2010 study period. Finally, we stratified our incidence esti-
mates by age-group (<6 months, 6–23 months, and 2–5
years) because we anticipated the proportion of CEMIC
children positive for respiratory viruses and the subsequent
rates might differ statistically by these age strata [17].
Costs associated with hospitalization
Administrative hospital records were examined for all
hospitalized children with acute respiratory illnesses to de-
termine room, laboratory, consumables, and physician
costs incurred by the pooled CEMIC account [18]. These
costs represented the amount of money CEMIC spent to
provide in-hospital care within the context of its non-for-
profit status. We converted CEMIC cost data in Argentin-
ean pesos to U.S. dollars using the average Argentina’s
Central Bank rate during June 2008–December 2010.
Ethics
The cohort study protocol was reviewed and approved
by the CEMIC Institutional Review Board (No.
00001745 IORG001315). Parents or guardians signed in-
formed consent forms to allow their children to partici-
pate in this investigation. The Centers for Disease
Table 1 Operationalization of commonly used case-definitions
• Severe acute lower respiratory infection: hospitalized children who had
cough or difficulty breathing (i.e., having tachypnea, or oxygen
requirement) with retractions [3]
• Severe acute respiratory infection: hospitalized children with subjective
fever and cough [27]
• Influenza-like illness: children who had sought care in emergency
room with subjective fever and cough [22]
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Control and Prevention (CDC) reviewed the protocol for
human subjects’ protection and determined to be non-
research because CDC staff was involved only after in-
formation had been collected and only analyzed non-
identifiable data.
Results
There were 1,729 children aged ≤ 5 years enrolled in
CEMIC in 2008, 1,838 in 2009 and 1,893 in 2010 (4,739
child-years of follow-up). During this study period, we
identified 89 hospitalizations (18.8/1000 child-years) and
8,925 emergency room visits (1.9/child-years) among
CEMIC children aged ≤ 5 years. We obtained detailed
clinical information from all 89 hospitalized children and
269 (3 %) of the 8,925 children who visited the emergency
room (89+ 269 = 358 study children) (Table 2). Hospital-
ized children were admitted for an average of median of
3 days; IQR, 2–4 days). One third (90) of children seeking
care at emergency room belonged to the CEMIC plan and
179 belonged to other insurance plans. In addition, med-
ical staff obtained nasopharyngeal swabs from 37 asymp-
tomatic control children.
Hospitalized children were younger (median age,
10 months; IQR, 4–23 months) than emergency room
children (median age, 18 months; IQR, 8–33 months)
and asymptomatic controls (median age, 43 months;
Table 2 Demographic and clinical characteristics of hospitalized, emergency room, and asymptomatic control children in Buenos
Aires during 2008–2010
Hospitalized Emergency room Controls
N = 89 CEMIC n = 90 Other n = 179 n = 37
Age (months) 10a 13 19 43b
Malesc 57 56 56 70
Preexisting conditions
Reactive airway diseasec 39 37 43 24
Tobacco exposurec 21 19 16 14
Late preterm birthc 19 13 13 16
Atopic dermatitisc 13 23 23 16
Birth weight <2,500 g 11 6 8 11
Vaccines and breastfeeding
Influenza vaccine if age >6 monthsc 31 37 50 26
Up-to-date with other vaccinesc 97 100 97 97
Breastfed (months) 5 6 6 6
Sign and Symptom
Fever >38°Cc 65 83 73
Coughc 92 89 87
Tachypneac 84a 45 42
Retractionsc 76a 24 20
Wheezingc 70a 41 34
Vomitingc 15 19 16
Diarrheac 10 10 7
Cyanosisc 2 1 1
Diagnoses
Rhinitisc 81a 89 91
Bronchiolitisc 74a 38 31
Pneumoniac 14a 5 7
Otitisc 8 9 7
Pharyngitisc 6a 36 35
Bronchitisc 1 10 7
Conjunctivitisc 0a 23 13
aStatistical difference between hospitalized versus emergency room children in rank-sum or Χ2 test, p < 0.05
bStatistical difference between ill (hospitalized and emergency room) children and control children in Wilcoxon rank-sum test, p < 0.001
cPercentage
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IQR, 24–60 months). Hospitalized children were also
more likely to present with tachypnea, retractions,
and wheezing and be diagnosed with bronchiolitis or
pneumonia than emergency room children (Table 2)
(Χ2 p < 0.03). Conversely, children were less likely to
be diagnosed with rhinitis, pharyngitis, or conjunctiv-
itis during their hospitalization than emergency room
children (Χ2 p < 0.04). There were no significant dif-
ferences between CEMIC and non-CEMIC children
seeking care at emergency room (Table 2).
Laboratory findings
All 358 hospitalized and emergency room children and
37 asymptomatic controls provided a nasopharyngeal as-
pirate or swab. While rhinoviruses were detected
throughout the year, RSV, human metapneumovirus, in-
fluenza, adenovirus, and parainfluenza 1 through 3
viruses were also identified starting April or May, with
peak activity during June or July, during Argentina’s aus-
tral winter (Fig. 1). RSV, human metapneumovirus, and
influenza were frequently identified among hospitalized
children aged <6 months (37, 18, 13 %, respectively) but
seldom among asymptomatic controls (<3 %) (Fig. 2).
Rhinovirus, however, was identified among 40 % of hos-
pitalized children and 22 % of asymptomatic controls
(Table 3). Only five patients tested positive for two vi-
ruses: two children were positive for RSV and influenza,
one for rhinovirus and RSV, one for rhinovirus and para-
influenza, and one for rhinovirus and adenovirus.
Children with laboratory-confirmed RSV typically
(>70 %) had presumptive diagnoses of bronchiolitis
while 56 % of those with laboratory-confirmed influenza,
had presumptive diagnoses of influenza illness. There
were no statistical differences in the proportion of
CEMIC children testing positive for specific respiratory
viruses each month at emergency room when compared
to the proportion of emergency room children from
other health plans (Χ2 p = 0.8). All 63 (71 %) of 89
hospitalized CEMIC children for who their clinicians
ordered blood cultures as part of routine clinical care,
tested negative for bacterial pathogens.
Incidence
The incidence of RSV (24/1000 children-years),
influenza (8/1000 children-years) and human metapneu-
movirus (8/1000 children-years) illnesses was highest
among hospitalized children aged <6 months and de-
creased among older children (Table 4). In contrast, the
incidence of rhinovirus was highest (12/1000 children-
years) among those aged 6–23 months. The incidence of
these respiratory viruses seemed lower when we limited
the analyses to children who met the severe acute lower
respiratory infection or severe acute respiratory infection
case-definitions. For example, while the incidence of
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Fig. 1 Proportion of children testing positive for respiratory viruses each month during 2008–2010 From July 2008 to December 2010, respiratory
samples from Argentina children aged ≤5 years, who were hospitalized or who sought care at an emergency room with any acute respiratory
infection sign or symptom (e.g., rhinorrhea, cough, wheezing, tachypnea, retractions, or cyanosis), were taken and tested for several respiratory
viruses (Human metapneumovirus, adenvirus, Para-influenza, influenza, RSV and rhinovirus). While rhinoviruses were detected throughout the year,
RSV, human metapneumovirus, influenza, adenovirus, and parainfluenza 1 through 3 viruses were also identified starting April or May, with peak
activity during June or July, during Argentina’s austral winter
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Fig. 2 Proportion of hospitalized, emergency room, and asymptomatic control children testing positive for respiratory viruses, 2008–2010. From
July 2008 to December 2010, respiratory samples from Argentina children aged ≤5 years, who were hospitalized or who sought care at an emergency
room with any acute respiratory infection sign or symptom (e.g., rhinorrhea, cough, wheezing, tachypnea, retractions, or cyanosis), were taken and
tested for several respiratory viruses (Human metapneumovirus, adenvirus, Para-influenza, influenza, RSV and rhinovirus). RSV, human
metapneumovirus, and influenza were frequently identified among hospitalized children aged <6 months (37, 18, 13 %, respectively) but
seldom among asymptomatic controls (<3 %). Rhinovirus, however, was identified among 40 % of hospitalized children and 22 % of
asymptomatic controls
Table 3 Numbera (and percentage) of hospitalized, emergency room, and asymptomatic control children testing positive for
respiratory viruses by age group in months during 2008–2010
Hospitalized Emergency room Asymptomatic control children
<6 6–23 24–71 0–71 <6 6–23 24–71 0–71 <6 6–23 24–71 0–71
RSV 9 (37) 14 (39) 3 (13) 26 (31) 7 (19) 16 (11) 12 (11) 35 (12) 0 (0) 0 (0) 1 (4) 1 (3)
Metapneumovirus 3 (18) 0 (0) 0 (0) 3 (5) 0 (0) 8 (6) 8 (8) 16 (6) 0 (0) 0 (0) 0 (0) 0 (0)
Influenza 3 (13) 2 (5) 4 (16) 9 (10) 3 (8) 13 (9) 21 (19) 37 (13) 0 (0) 0 (0) 0 (0) 0 (0)
Rhinovirus 2 (12) 13 (46) 10 (56) 25 (40) 13 (37) 40 (29) 18 (17) 71 (26) 1 (33) 2 (33) 5 (18) 8 (22)
Adenovirus 0 (0) 1 (3) 0 (0) 1 (1) 0 (0) 4 (3) 2 (2) 6 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Parainfluenza 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 13 (9) 4 (4) 17 (6) 0 (0) 0 (0) 0 (0) 0 (0)
Any virusb 17 (71) 27 (67) 17 (68) 61 (69) 21 (58) 89 (61) 60 (55) 170 (58) 1 (33) 2 (33) 6 (21) 9 (24)
From July 2008 to December 2010, respiratory samples from Argentina children aged ≤5 years, who were hospitalized or who sought care at an emergency room
with any acute respiratory infection sign or symptom (e.g., rhinorrhea, cough, wheezing, tachypnea, retractions, or cyanosis), were taken and tested for several
respiratory viruses (Human metapneumovirus, adenovirus, Para-influenza, influenza, RSV and rhinovirus). RSV, human metapneumovirus, and influenza were frequently
identified among hospitalized children aged <6 months (37, 18, 13 %, respectively) but seldom among asymptomatic controls (<3 %). Rhinovirus, however, was identified
among 40 % of hospitalized children and 22 % of asymptomatic controls. Co-infections were an uncommon event in our study. Only five patients tested positive for two
viruses: two children were positive for RSV and influenza, one for rhinovirus and RSV, one for rhinovirus and parainfluenza, and one for rhinovirus and adenovirus (results
not shown)
aAlthough all children for tested for all viruses, some samples yielded unreadable results. The unreadable results were excluded from the analysis. Therefore, there
was some variation in the denominator for each virus
bThe number of viruses detected in each column may not add up to the number of children with at least one virus because some children had coinfections
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RSV respiratory illnesses was 6/1000 children-years
among hospitalized children aged ≤5 years, only half
of these met the severe acute lower respiratory infec-
tion case-definition (3/1000 children-years). In emer-
gency rooms, the incidence of rhinovirus was 459
(95 % CI, 121–869)/1,000 children-years; RSV 352
(95 % CI, 167–557); influenza 185 (95 % CI, 57–333);
parainfluenza 177 (95 % CI, 15–400); metapneumo-
virus 130 (95 % CI, 7–276); and adenovirus 73 (95 %
CI, 2–180). Eighty-three percent of children seeking
care at emergency room for laboratory-confirmed in-
fluenza illness met the ILI case definition.
Hospitalization costs
The total cost of hospitalization to CEMIC was a me-
dian of US$529 (IQR, US$362–789). Fifty-nine percent
of the total cost was comprised room charges (median
US$310 [IQR US$227–517]). Consumables represented
13 % (median US$ 66 [IQR US$38–129); diagnostic as-
says, 12 % (median US$64 [IQR US$54–99]); medica-
tions, 10 % (median US$54 [IQR US$27–148]); and
consults with specialists, 6 % (median US$30 [IQR
US$0–60]) of the total costs.
Discussion
Our findings suggest that respiratory viruses including
rhinovirus, RSV, influenza, and human metapneumo-
virus in particular may have caused a substantial disease
and economic burden among Argentinean children aged
≤5 years. This RSV burden was highest among the youn-
gest children with an incidence similar to that docu-
mented in other countries [3]. Indeed, very young
children are more likely to require hospitalization as a
result of viral respiratory illness [19]. Although RSV vac-
cines are under development, none are licensed for use
among children. The national program in Argentina rec-
ommends that palivizumab prophylaxis be given to all
preterm children with a gestational age of < 29 weeks or
to preterm children with a gestational age of 29–32
weeks and bronchopulmonary dysplasia during RSV
epidemics to decrease the probability of severe respira-
tory infections. To improve the value of palivizumab,
surveillance staff should provide pediatricians with
timely information about RSV epidemics in their com-
munity, especially during the austral winter when such
epidemics are anticipated.
In our study, approximately ten percent of hospitalized
and emergency room children had influenza infections.
The incidence of influenza-related hospitalizations was
substantial (2/1,000 children-years) and comparable with
that of sites that estimated the seasonal and 2009 pan-
demic influenza incidence, and invest in influenza vaccine
programs [20]. The cost associated with hospitalization
was also substantial (~US$500/hospitalization) and would
represent a little less than 1/2 of the median monthly net
household income in Argentina during 2008–2010
(US$1235/month [IQR US$1102–1366) [21]. Indeed, the
cost of hospitalization would have been even higher
among children admitted to intensive care where the
length of stay was an average of 8 days rather than 3 days
like in the general pediatric ward.
In our study, approximately 30 % of children aged
>6 months had been vaccinated against influenza. South-
ern hemisphere vaccines were well-matched to the pre-
dominant influenza strains characterized in Argentina
during the study period, except during the 2009 influ-
enza A (H1N1) pandemic [22]. It is reasonable to as-
sume that the influenza burden among CEMIC children
would have been lower if influenza vaccine coverage had
been higher [23]. Institutions like CEMIC should explore
how to improve influenza vaccine utilization among chil-
dren aged > 6 months such that it is administered on par
with that of other pediatric vaccines. Argentina adopted
pneumococcal vaccination in 2012 [24] and institutions
like CEMIC may also want to explore the additional im-
pact of pneumococcal and influenza vaccination on early
childhood morbidity.
Rhinoviruses were frequently detected in our pediatric
population. Rhinoviruses are among the most frequent
causes of the common cold and have been associated
Table 4 Incidence of respiratory viruses per 1000 hospitalized children per year, 2008–2010
Hospitalized with at least one respiratory sign or
symptom
Severe acute lower respiratory
infection
Severe acute respiratory
infection
<6 6–23 24–71 All <6 6–23 24–71 All <6 6–23 24–71 All
RSV 24 13 1 6 13 11 0.4 4 13 10 0.7 4
Metapneumovirus 8 - - 1 5 - - 0.5 3 - - 0.2
Influenza 8 2 1 2 3 - 0.4 0.5 3 1 1 1
Adenovirus - 1 - 0.2 - 0.9 - 0.2 - 1 - 0.2
Parainfluenza - - - - - - - - - - - -
Rhinovirus 5 12 4 6 3 8 3 4 3 5 2 3
The incidence of RSV (24/1000 children-years), influenza (8/1000 children-years) and human metapneumovirus (8/1000 children-years) illnesses was highest among
hospitalized children aged <6 months and decreased among older children. In contrast, the incidence of rhinovirus was highest (12/1000 children-years) among
those aged 6–23 months
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with lower respiratory infections [25]. Previously, we re-
ported that rhinovirus had a prevalence of 27 % among
outpatient children [14] and 47 % among hospitalized
children aged ≤5 years in Argentina [1]. In our current
study, we detected rhinovirus among 2/5 of hospitalized
children and 1/5 of asymptomatic controls. In our study,
a substantive number of children had a severe respira-
tory illnesses requiring hospitalization that seem to have
been precipitated by rhinovirus infections. We were un-
able to determine which proportion of these hospitaliza-
tions was directly attributable to rhinovirus illness
because we did not follow asymptomatic children pro-
spectively to determine if they subsequently developed
illness and because these children were typically older
than hospitalized children. Indeed, given the frequency
of rhinovirus infections and our lack of follow up among
control children, it was not possible to determine
whether rhinovirus positive asymptomatic children were
shedding virus from an illness that occurred >2 weeks
before their enrolment, were currently asymptomatic
but about to develop signs and symptoms of clinical ill-
ness, or had a subclinical infection. More data are
needed to fully understand the natural history of chil-
dren with rhinovirus infections, the clinical impact of
rhinoviruses and the potential value of antivirals and
vaccines targeting these viruses [26].
During our statistical analyses, we noted that our inci-
dence estimates varied substantially depending on the
case-definitions we used. For example, while the inci-
dence of laboratory-confirmed influenza among children
hospitalized for the management of an illness with at
least one sign or symptom of respiratory infection was
2/1000 children-years, the incidence was 1/1000
children-years among those who met the severe acute
lower respiratory infection or severe acute respiratory
infection case-definitions [27]. Similarly 4/5 of children
at emergency room with laboratory-confirmed influenza
illness met the ILI case-definition typically used by influ-
enza surveillance platform throughout the Americas
[22]. Investigators seeking to estimate the burden of
RSV, influenza, human metapneumovirus, and other re-
spiratory viruses should be aware of the impact case-
definitions have on their estimates depending on the age
of group studied and local health seeking practices [6].
Our cohort study had several important limitations.
We enrolled children without underlying conditions be-
cause these represented the majority of the CEMIC
population. Aside from acute respiratory infections, par-
ticipating children were otherwise healthy. It is likely
that our incidence estimates would have been higher if
we had also enrolled children with comorbidities such as
pulmonary dysplasia, immunodeficiencies and cardiopa-
thies because these are known risk factors for complica-
tions and hospitalizations from respiratory virus illnesses
[8]. RSV, human metapneumovirus, influenza, parainflu-
enza 1–3, and adenovirus were detected through direct
antigen detection by immunofluorescence. This low-cost
assay is readily available throughout Latin America [27]
but has a lower sensitivity than polymerase chain reaction
(PCR) [28]. It is therefore possible that the incidence of
these viruses may have been higher if we had tested all
samples through PCR. We were also unable to randomly
sample asymptomatic control children from both study
sites of the same age and during the same epidemiologic
week as hospitalized case-patients because of limited re-
sources and because CEMIC parents seldom provided
consent for nasopharyngeal swabs if their children were
asymptomatic during preventive care visits. As a result,
asymptomatic control children were typically older than
cases and consequently had a lower probability of testing
positive for key respiratory viruses (e.g., RSV). Last, we ob-
tained 2 ½ years of respiratory specimens from a conveni-
ence sample of 1 % of emergency room patients, a
subpopulation that may not have been representative of
all CEMIC children, the 8,925 children who sought emer-
gency room care during the study period, or children
throughout Argentina during 2008–2010.
Conclusions
Our study suggests that the incidence of rhinovirus,
RSV, human metapneumovirus and influenza among
hospitalized and emergency room children was substan-
tive. Children aged <6 months were most commonly af-
fected during Argentina’s austral winter. Respiratory
virus illnesses were associated with costly hospitaliza-
tions. Institutions like CEMIC should explore the poten-
tial value of promoting hand washing, cough etiquette,
and other non-pharmaceutical interventions aimed at
interrupting respiratory virus transmission among fam-
ilies with very young children. Pending the availability of
vaccines for RSV and other respiratory viruses, CEMIC
and the Argentina Ministry of Health could also explore
the impact of influenza vaccination among pregnant
women and children aged 6 months to 5 years as recom-
mended by the World Health Organization’s Strategic
Advisory Group of Experts on Immunization [29].
Abbreviations
AdV: Adenovirus; ARI: Acute respiratory infection; CEMIC: Centro de
Educación Médica e Investigaciones Clínicas; CDC: U.S. Centers for Disease
Control and Prevention; CI: Confidence interval; FluA: Influenza A;
FluB: Influenza B; HMPV: Human metapneumovirus; If: Immunofluorescence;
IQR: Interquartile range; PIV: Parainfluenza virus; RSV: Respiratory syncytial
virus; RT-PCR: Reverse transcription polymerase chain reaction; US/
USA: United States of America.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DNM participated in the data collection, analyses, and editing of manuscript.
LOD participated in the design, data analysis and writing of the manuscript.
Marcone et al. BMC Infectious Diseases  (2015) 15:447 Page 8 of 9
EAB participated in the design, data analysis and writing of the manuscript.
SV participated in interpretation of clinical findings and editing of the manuscript.
JE participated in interpretation of clinical findings and editing of the manuscript.
GC participated in the initial study the design, interpretation of findings and
editing of the manuscript. ME participated in the initial design of the study,
data analyses, interpretation of findings and editing of the manuscript. All authors
read and approved the final version of the manuscript.
Acknowledgements
We thank Cristina Videla and Carmen Ricarte for technical assistance and
Livia Zarini, Claudio Facio, Alejandra Gutlein, and Sandra Gomez for statistical
and financial data collection. We also thank Marc-Alain Widdowson, Joseph
Bresee, Susan Gerber, Cecilia Gonzales, Daniel Bausch, and Harish Nair for the
enriching discussions regarding case definitions and for assistance with the
funding of the project.
Disclaimers
This study has been funded through a grant awarded to Dr. Echavarria from
the Agencia Nacional de Promoción Científica y Tecnológica (PICT 2006–650),
Argentina and a grant from the Centers for Disease Control and Prevention (an
agency of the U.S. Department of Health and Human Services), which is
administered from an Interagency Agreement between U.S. CDC, U.S. Naval
Medical Research Unit Number-6 and CEMIC). None of the coauthors have any
conflicts of interest to declare. The findings and conclusions in this report are
those of the authors and do not necessarily represent the official position of the
Centers for Disease Control and Prevention or other institutions with which the
authors are affiliated.
Author details
1Virology Unit and Clinical Virology Laboratory, Centro de Educación Médica
e Investigaciones Clínicas “CEMIC” and CONICET, Galván 4102, 1431 FWO
Buenos Aires, Argentina. 2Centers for Disease Control and Prevention, 1600
Clifton Rd, NE, MS A32, Atlanta GA 30329-4018Georgia, USA. 3Department of
Pediatrics, Centro de Educación Médica e Investigaciones Clínicas “CEMIC”,
Buenos Aires, Argentina.
Received: 25 March 2015 Accepted: 13 October 2015
References
1. Marcone D, Ellis A, Videla C, Ekstrom J, Ricarte C, Carballal G, et al. Viral
etiology of acute respiratory infections in hospitalized and outpatient
children in Buenos Aires. Argentina Pediatr Infect Dis J. 2013;32:e105–10.
2. Nair H, Brooks W, Katz M, Roca A, Berkley JA, Madh SA, et al. Global burden
of respiratory infections due to seasonal influenza in young children: a
systematic review and meta-analysis. Lancet. 2011;378:1917–30.
3. Nair H, Nokes D, Gessner B, Dherani M, Madhi SA, Singleton RJ, et al. Global
burden of acute lower respiratory infections due to respiratory syncytial
virus in young children: a systematic review and meta-analysis. Lancet.
2010;375:1545–55.
4. Videla C, Carballal G, Misirlian A, Aguilar M. Acute lower respiratory infections
due to respiratory syncytial virus and adenovirus among hospitalized children
from Argentina. Clin Diagn Virol. 1998;10:17–23.
5. Zeng S, Xiao N, Xie Z. Prevalence of human rhinovirus in children admitted
to hospital with acute lower respiratory tract infections in Changsha, China.
J Med Virol. 2014;86(11):1983–9.
6. Nair H, Campbell H, Mounts A. A manual for estimating disease burden
associated with seasonal influenza in a population. Geneva, Switzerland:
World Health Organization; 2009.
7. Talaat M, Afifi S, Dueger E, El-Ashry N, Marfin A, Kandeel A, et al. Effects of
hand Hygiene Campaigns on Incidence of Laboratory-confirmed Influenza
and Absenteeism in Schoolchildren, Cairo, Egypt. Emerg Infect Dis.
2011;1–16. http://dx.doi.org/10.3201/eid1704.101353
8. CDC says “Take 3” actions to fight the flu [http://www.cdc.gov/flu/protect/
preventing.htm]
9. Omer S, Goodman D, Steinhoff M, Rochat R, Klugman K. Maternal influenza
immunization and reduced likelihood of prematurity and small for
gestational age births: a retrospective cohort study. PLoS Med.
2011;8:e1000441.
10. Educación Permanente en Pediatría, Influenza [http://www.ms.gba.gov.ar/
sitios/pediatria/influenza-2013]
11. Ropero-Alvarez A, Kurtis H, Danovaro-Holliday M, Ruiz-Matus C, Andrus J.
Expansion of seasonal influenza vaccination in the Americas. BMC Public
Health. 2009;361:1–9.
12. What is PedNSS/PNSS? PedNSS health indicators [http://www.cdc.gov/
pednss/what_is/pednss_health_indicators.htm]
13. Health AMo: Winter campaign, Argentina 2010. pp. 1–17. Buenos Aires,
Argentina; 2010:1–17. http://www.buenosaires.gob.ar/sites/gcaba/files/
calendario_vacunacion.pdf.
14. Marcone D, Videla C, Ricarte C, Carballal G, Vidaurreta S, Echavarría M. Rhinovirus
detection by real-time RT-PCR in children with acute respiratory infection. Rev
Argent Microbiol. 2012;44:259–65.
15. Homaira N, Luby S, Petri W, Vainionpaa R, Mustafizur R, MK H. Incidence of
respiratory virus-associated pneumonia in urban poor young children of
Dhaka, Bangladesh, 2009–2011. PLoS One. 2012;7:e32056.
16. Azziz-Baumgartner E, Alamgir A, Rahman M, Homaira N, Sohel B: Incidence
of influenza-like illness and severe acute respiratory infection during three
influenza seasons in Bangladesh, 2008–2010. Bulletin of the World Health
Organization. 2012;90(1):12-19. doi:10.2471/BLT.11.090209.
17. Azziz-Baumgartner E, Cabrera AM, Chang L, Calli R, Kusznierz G, Baez C, et al.
Mortality, severe acute respiratory infection, and influenza like-illness
associated with Influenza A (H1N1) pdm09 in Argentina, 2009. PLoS One.
2012;7:e47540.
18. Bhuiyan M, Luby S, Alamgir N, Homaira N, Mamun AA, Khan JA, et al.
Economic burden of influenza-associated hospitalizations and outpatient
visits in Bangladesh during 2010. Influenza Other Respir Viruses.
2014;8(4):406-13. doi:10.1111/irv.12254. Epub 2014 April 22.
19. Izurieta H, Thompson W, Kramarz P, et al. Influenza and the rates of
hospitalization for respiratory disease among infants and young children.
New Engl J Med. 2000;342:232–9.
20. Clara W1, Armero J, Rodriguez D, Lozano C, Bonilla L, Minaya P, et al.
Estimated incidence of influenza-associated severe pneumonia in children
in El Salvador, 2008–2010. WHO Bulletin. 2012;10:90.
21. Encuesta Nacional de Ingresos y Gastos de los Hogares 2012 [http://www.
indec.gov.ar/bajarSerieHistorica.asp?idc=3E39C582938004648519257
AB123794175C8EA2CB3D7EBC9EC9D878E3EFB3392484F48EDE2037643]
22. Global influenza surveillance and response system [http://www.who.int/
influenza/gisrs_laboratory/en/]
23. Kostova D, Reed C, Finelli L, Cheng P, Gargiullo P, Shay D. Influenza illness
and hospitalizations averted by influenza vaccination in the United States,
2005–2011. PLoS One. 2013;8(6):e66312.
24. Vacuná a tus hijos contra el Neumococo [http://www.msal.gov.ar/index.php/
component/content/article/46/178-vacuna-a-tus-hijos-contra-el-neumococo]
25. Rosenstein N, Phillips W, Gerber M, Marcy S, Schwartz B, Dowell S. The
common cold. Principles of judicious use of antimicrobial agents. Pediatrics.
1998;101:181–4.
26. Brownlee J, Turner R. New developments in the epidemiology and clinical
spectrum of rhinovirus infections. Curr Opin Pediatr. 2008;20:67–71.
27. Operational guidelines for intensified SARI surveillance [http://www.paho.
org/hq/index.php?option=com_docman& task=doc_view& gid=17125&
Itemid=.Accessed]
28. Atmar R, Baxter B, Dominguez E, Taber L. Comparison of reverse
transcription-PCR with tissue culture and other rapid diagnostic assays for
detection of type a influenza virus. J Clin Microbiol. 1996;34:2604–6.
29. SAGE Meetings [http://www.who.int/influenza/vaccines/SAGE_
information/en/]
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Marcone et al. BMC Infectious Diseases  (2015) 15:447 Page 9 of 9
